Published since 1965, Laser Focus World provides comprehensive global coverage of optics, photonics, and optoelectronic technologies, applications, and markets. With 80,000+ qualified print subscribers in print and over a half-million annual visitors to our online content, we are the go-to source to access decision makers and stay in-the-know.

In addition to providing in-depth articles written by Laser Focus World editors, Laser Focus World accepts articles, news stories, and new product information for publication from qualified outside contributors. For more information on submitting articles and other optoelectronics-related material to Laser Focus World, please use the following links:

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.

The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions.

The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.